STEM CELL THERAPY VS
CAR-T THERAPY
In second-line DLBCL, randomised trials (ZUMA-7, TRANSFORM) showed CAR-T outperforms autologous HSCT. For most other situations, they are different tools for different jobs β often used in sequence, not competition.
What This Means for Patients
DLBCL second-line: ZUMA-7 (axi-cel) and TRANSFORM (liso-cel) showed CAR-T superior EFS vs autologous HSCT β practice-changing. B-ALL: CAR-T achieves remission then bridges to allogeneic HSCT (sequential, not competitive). Myeloma: CAR-T for relapsed/refractory, autologous HSCT for frontline consolid
Key Insights
Understanding this topic is essential for informed transplant decisions.
Clinical Relevance
Directly impacts transplant planning, risk assessment, and understanding of what each phase of the procedure accomplishes and requires.
For Patients and Families
Knowledge enables better-informed questions, realistic expectations, and active participation in transplant decisions alongside the clinical team.
Benefits and Limitations
Benefits
- Allogeneic HSCT provides documented cures for specific haematologic malignancies
- Modern advances (PTCy, RIC, new GVHD agents) expanded access and improved outcomes
- Decades of randomised trial data support disease-specific transplant indications
Limitations
- Treatment-related mortality is a real risk requiring specialist centre expertise
- GVHD remains a significant complication requiring long-term management
- Full recovery timeline is longer than most patients initially expect
Frequently Asked Questions
About This Topic
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Evaluating Stem Cell Transplant Options?
CancerFax connects patients with specialist transplant centres, comprehensive evaluation, and access to advanced cellular therapy programmes worldwide.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.